key: cord-0935419-hadaanjv
authors: Halfmann, Peter J.; Iida, Shun; Iwatsuki-Horimoto, Kiyoko; Maemura, Tadashi; Kiso, Maki; Scheaffer, Suzanne M.; Darling, Tamarand L.; Joshi, Astha; Loeber, Samantha; Singh, Gagandeep; Foster, Stephanie L.; Ying, Baoling; Case, James Brett; Chong, Zhenlu; Whitener, Bradley; Moliva, Juan; Floyd, Katharine; Ujie, Michiko; Nakajima, Noriko; Ito, Mutsumi; Wright, Ryan; Uraki, Ryuta; Warang, Prajakta; Gagne, Matthew; Li, Rong; Sakai-Tagawa, Yuko; Liu, Yanan; Larson, Deanna; Osorio, Jorge E.; Hernandez-Ortiz, Juan P.; Henry, Amy R.; Ciuoderis, Karl; Florek, Kelsey R.; Patel, Mit; Odle, Abby; Wong, Lok-Yin Roy; Bateman, Allen C.; Wang, Zhongde; Edara, Venkata-Viswanadh; Chong, Zhenlu; Franks, John; Jeevan, Trushar; Fabrizio, Thomas; DeBeauchamp, Jennifer; Kercher, Lisa; Seiler, Patrick; Gonzalez-Reiche, Ana Silvia; Sordillo, Emilia Mia; Chang, Lauren A.; van Bakel, Harm; Simon, Viviana; Douek, Daniel C.; Sullivan, Nancy J.; Thackray, Larissa B.; Ueki, Hiroshi; Yamayoshi, Seiya; Imai, Masaki; Perlman, Stanley; Webby, Richard J.; Seder, Robert A.; Suthar, Mehul S.; García-Sastre, Adolfo; Schotsaert, Michael; Suzuki, Tadaki; Boon, Adrianus C. M.; Diamond, Michael S.; Kawaoka, Yoshihiro
title: SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters
date: 2022-01-21
journal: Nature
DOI: 10.1038/s41586-022-04441-6
sha: 613f49258dadc8c69ebd37b6d369d2971087b15a
doc_id: 935419
cord_uid: hadaanjv

The recent emergence of B.1.1.529, the Omicron variant(1,2), has raised concerns of escape from protection by vaccines and therapeutic antibodies. A key test for potential countermeasures against B.1.1.529 is their activity in preclinical rodent models of respiratory tract disease. Here, using the collaborative network of the SARS-CoV-2 Assessment of Viral Evolution (SAVE) programme of the National Institute of Allergy and Infectious Diseases (NIAID), we evaluated the ability of several B.1.1.529 isolates to cause infection and disease in immunocompetent and human ACE2 (hACE2)-expressing mice and hamsters. Despite modelling data indicating that B.1.1.529 spike can bind more avidly to mouse ACE2 (refs. (3,4)), we observed less infection by B.1.1.529 in 129, C57BL/6, BALB/c and K18-hACE2 transgenic mice than by previous SARS-CoV-2 variants, with limited weight loss and lower viral burden in the upper and lower respiratory tracts. In wild-type and hACE2 transgenic hamsters, lung infection, clinical disease and pathology with B.1.1.529 were also milder than with historical isolates or other SARS-CoV-2 variants of concern. Overall, experiments from the SAVE/NIAID network with several B.1.1.529 isolates demonstrate attenuated lung disease in rodents, which parallels preliminary human clinical data.

The recent emergence of B.1.1.529, the Omicron variant 1,2 , has raised concerns of escape from protection by vaccines and therapeutic antibodies. A key test for potential countermeasures against B.1.1.529 is their activity in preclinical rodent models of respiratory tract disease. Here, using the collaborative network of the SARS-CoV-2 Assessment of Viral Evolution (SAVE) programme of the National Institute of Allergy and Infectious Diseases (NIAID), we evaluated the ability of several B.1.1.529 isolates to cause infection and disease in immunocompetent and human ACE2 (hACE2)-expressing mice and hamsters. Despite modelling data indicating that B.1.1.529 spike can bind more avidly to mouse ACE2 (refs. 3, 4 ), we observed less infection by B.1.1.529 in 129, C57BL/6, BALB/c and K18-hACE2 transgenic mice than by previous SARS-CoV-2 variants, with limited weight loss and lower viral burden in the upper and lower respiratory tracts. In wild-type and hACE2 transgenic hamsters, lung infection, clinical disease and pathology with B.1.1.529 were also milder than with historical isolates or other SARS-CoV-2 variants of concern. Overall, experiments from the SAVE/NIAID network with several B.1.1.529 isolates demonstrate attenuated lung disease in rodents, which parallels preliminary human clinical data.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic resulting in millions of deaths worldwide. The extensive morbidity and mortality made the development of vaccines, antibody-based countermeasures and antiviral agents a global health priority. As part of this process, several models of SARS-CoV-2 infection and lung pathogenesis were developed in animals for rapid testing 5 . Remarkably, several highly effective vaccines and therapeutics were deployed with billions of doses given worldwide. Although these measures markedly reduced hospitalizations and deaths, their efficacy has been jeopardized by the emergence of SARS-CoV-2 variants with mutations in the spike gene.

The SARS-CoV-2 spike protein engages angiotensin-converting enzyme 2 (ACE2) on the surface of human cells to facilitate entry and infection of cells 6 . Upon cell attachment, spike proteins are cleaved by host proteases into S1 and S2 fragments. The S1 protein includes the amino-terminal (NTD) and receptor-binding (RBD) domains. The RBD is the target of many potently neutralizing monoclonal [7] [8] [9] [10] [11] and serum polyclonal 12 antibodies. Although SARS-CoV-2 spike proteins from strains early in the pandemic bound to ACE2 from several animal species (for example, hamster, ferret and nonhuman primates), they did not bind mouse ACE2, which explained why laboratory strains of mice could not be infected by SARS-CoV-2 (refs. 6, 13 ); indeed, mice could become susceptible through expression of hACE2 via a transgene [14] [15] [16] or viral vector 17, 18 , or under regulation of the mouse ACE2 promoter [19] [20] [21] . Later in the pandemic, several strains acquired a mouse-adapting spike substitution (N501Y), which allowed engagement of mouse ACE2 and productive infection of mice without hACE2 expression [22] [23] [24] .

In late November 2021, the Omicron (B.1.1.529) variant emerged. This variant has the largest number (>30) of substitutions, deletions Article or insertions in the spike protein described so far, raising concerns of escape from protection by vaccines and therapeutic monoclonal antibodies. B.1.1.529 isolates have many changes in the RBD (G339D,  R346K, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K,  E484A , Q493R, G496S, Q498R, N501Y and Y505H). The N501Y substitution along with changes at sites (K417, E484, Q493, Q498 and N501) associated with mouse adaptation [25] [26] [27] [28] [29] [30] (Fig. 1a) . Similarly, aged (10-to 14-month-old) C57BL/6 mice also did not lose weight after B.1.1.529 infection, whereas those infected with B.1.351 did (Fig. 1a) . 

We next compared viral burden in B.1.1.529-and B.1.351-infected 129 mice. At 3 dpi, 129 mice infected with B.1.351 sustained high levels of infection in the nasal wash, nasal turbinates and lungs (Fig. 1b) . The levels of viral RNA in the nasal turbinates and lungs of B.1.1.529-infected mice were 10-to 100-fold lower than those in B.1.351-infected animals (Fig. 1b) . Similar results were seen in a separate cohort of 129 mice at 4 dpi, with 1,000-to 100,000-fold less infectious virus recovered from nasal turbinates and lungs of animals infected with B.1.1.529 compared to B.1.351 (Fig. 1c) .

Members of the group also tested B.1.1.529 in BALB/c mice. At 2 dpi, infectious virus levels in the nasal turbinates and lungs were significantly lower (≈1,000-fold, P < 0.001) in BALB/c mice infected with B.1.1.529 compared to B.1.351 (Fig. 1d) . We used whole-body plethysmography 35 to measure pulmonary function in infected mice. At 2 dpi, whereas B.1.351 caused an increase (P < 0.001) in the lung enhanced pause (Penh), a marker of bronchoconstriction, B.1.1.529 did not (Fig. 1e) . The ratio of peak expiratory flow (Rpef) also was decreased at 2 dpi in BALB/c mice infected with B.1.351 but not B.1.1.529 (P < 0.001, Fig. 1e) .

Two of our groups tested B.1.1.529 infection in K18-hACE2 transgenic mice, which express hACE2 under an epithelial cytokeratin promoter 14 , and are more susceptible to SARS-CoV-2 infection 16 . At intranasal doses ranging from 10 3 to 10 5 infectious units of B.1.1.529, weight loss was not observed over the first 5 to 6 days of infection in younger or older K18-hACE2 mice (Fig. 1f) . These data contrast with historical results with WA1/2020 D614G or variant (for example, B.1.351) SARS-CoV-2 strains 16,24,34,36 , which uniformly induce weight loss starting at 4 dpi. The groups separately observed reduced levels of infectious B.1.1.529 compared to WA1/2020 D614G or B.1.351 in the lower respiratory tracts at 3 dpi (Fig. 1g, h) . Finally, we assessed inflammatory responses in the lungs of K18-hACE2 mice at 3 dpi. Mice inoculated with B.1.1.529 had lower levels of several pro-inflammatory cytokines and chemokines compared to those inoculated with B.1.351, with many values similar to those of uninfected controls ( Fig. 1i and Supplementary Table 3 ). Thus, on the basis of several parameters (weight change, viral burden, respiratory function measurements and cytokine responses), B.1.1.529 seems attenuated in the respiratory tract of several strains of mice.

Four members of our group tested three different B.1.1.529 strains for their ability to infect and cause disease (Supplementary Table 1 ). Whereas intranasal infection with historical or other variant SARS-CoV-2 strains generally resulted in ≈10 to 15% reduction in body weight over the first week, we observed no weight loss in hamsters inoculated with B.1.1.529 (Fig. 2a-d) , although animals did not gain body weight as rapidly as uninfected hamsters. Viral RNA analysis at 4 dpi showed lower levels of B.1.1.529 infection in the lungs (12-fold, P < 0.001) compared to WA1/2020 D614G (Fig. 2e) Table 1 for more information. (Fig. 2g) . Thus, in hamsters infected with B.1.1.529, the upper, but not the lower, respiratory tract infection seems relatively intact.

We used whole-body plethysmography to measure pulmonary function in infected Syrian hamsters. Starting at 3 dpi and continuing until 7 dpi, infection with B.1.617.2 caused an increase (P < 0.05) in the Penh, whereas B.1.1.529 infection did not (Fig. 2h, left) . The Rpef was decreased at 5 and 7 dpi in animals infected with B.1.617.2 but not B.1.1.529 (P < 0.001; Fig. 2h, middle) . Finally, hamsters infected with B.1.617.2, but not B.1.1.529, demonstrated a decrease in respiratory rate (frequency) compared to uninfected animals (Fig. 2h, right) . On the basis of several functional parameters, lung infection and disease after B.1.1.529 infection was attenuated compared to that after infection with other variant strains.

We performed microcomputed tomography (micro-CT) to assess for lung abnormalities in hamsters at 7 dpi. Micro-CT analysis revealed lung abnormalities in all B.1.617.2-infected hamsters on 7 dpi that were consistent with commonly reported imaging features of COVID-19 pneumonia 37 . In comparison, analysis of B.1.1.529-infected hamsters on 7 dpi revealed patchy, ill-defined ground-glass opacity consistent with minimal to mild pneumonia. Syrian hamsters infected with B.1.617.2 had a much higher CT disease score 35 than those infected with B.1.1.529 (Fig. 2i, j) .

Members of our group also compared lung pathology in Syrian hamsters after infection with B.1.617.2 or B.1.1.529. The lungs obtained from B.1.617.2-infected hamsters showed congestion and/ or haemorrhage, which were absent in B.1.1.529-infected animals (Fig. 3a) . Immune cell infiltration and inflammation were present in the peribronchial regions of the lungs at 3 dpi with B.1.617.2. At 6 dpi, extensive infiltration of neutrophils and lymphocytes in the alveolar space was accompanied by pulmonary edema and haemorrhage (Fig. 3b, inset) , and regenerative changes in the bronchial epithelia became prominent (Fig. 3b) . By contrast, in B.1.1.529-infected hamsters, small foci of inflammation in the alveoli and peribronchial regions were observed only at 6 dpi (Fig. 3b) . A worse histopathology score of viral pneumonia at 6 dpi was measured after B.1.617.2 than B.1.1.529 infection (Fig. 3c) . After B.1.617.2 infection, viral RNA was detected readily in the alveoli and bronchial epithelia at 3 and 6 dpi (Fig. 3d) . After B.1.1.529 infection, fewer bronchial epithelial cells and alveoli were positive for viral RNA at either time point (Fig. 3d) . Thus, B.1.1.529 replicates less efficiently in the lungs of Syrian hamsters, which results in less severe pneumonia compared to that resulting from the B.1.617.2 variant.

Although hamster ACE2 can serve as a receptor for the SARS-CoV-2 spike protein, some of the contact residues in hACE2 are not conserved 38 , which could diminish infectivity. To develop a more susceptible hamster model, members of the consortium used transgenic hamsters expressing hACE2 under the epithelial cytokeratin-18 promoter 39 . Whereas intranasal inoculation of 10 3 PFU of HP-095 D614G virus resulted in marked weight loss within the first week (Fig. 2k) and uniform mortality by 10 dpi (Fig. 2l) , less weight loss and death (P < 0.05) were observed after infection with B.1.1.529. Moreover, 1,000-to 10,000-fold lower levels of infectious virus were measured in the lungs of hACE2 transgenic hamsters challenged with B.1.1.529 than in those challenged with HP-095 D614G at 3 and 5 dpi (Fig. 2m) . As seen in wild-type Syrian hamsters, smaller differences in infection were observed in the nasal turbinates. Thus, B.1.1.529 infection in the lung is attenuated in both wild-type and hACE2 transgenic hamsters.

Our experiments indicate that the B.1.1.529 variant is less pathogenic in laboratory mice and hamsters. Although these results are consistent with preliminary data in humans 40, 41 , the basis for attenuation remains unknown. One study indicates that B.1.1.529 replicates faster in the human bronchus and less in lung cells, which may explain its greater transmissibility and putative lower disease severity 42 . We observed that B.1.1.529 resulted in a lower level of infection of hamster bronchial cells in vivo and lower viral burden in nasal washes and turbinates in mice compared with other SARS-CoV-2 strains. The attenuation in mice was unexpected given that B.1.1.529 has alterations in the RBD that are sites associated with adaptation for mice [25] [26] [27] . The attenuation in hamsters seen by our group and others 43 was also surprising, given that other SARS-CoV-2 variants replicate to high levels in this animal 35, 44, 45 . Whereas the >30 changes in the B.1.1.529 spike protein could impact receptor engagement, changes in other proteins could affect replication, temperature sensitivity, cell and tissue tropism, and induction of pro-inflammatory responses in a species-specific manner. Our results showing attenuated B.1.1.529 infection in laboratory mice do not support the suggestion that B.1.1.529 has a mouse origin 4 . However, infection studies in wild mice 46 are needed to fully address this question.

Although B.1.1.529 is less pathogenic in mice and hamsters, these animals still will have utility in evaluating vaccine, antibody or small-molecule inhibitors. The mice and hamsters tested, to varying degrees, showed evidence of viral replication and dissemination to the lower respiratory tract, which could be mitigated by countermeasures. The most severe B.1.1.529 infection and disease was observed in hACE2-expressing mice and hamsters, which is consistent with findings for other SARS-CoV-2 strains 16, 24, 39, 47 , and possibly related to the enhanced interactions between hACE2 and B.1.1.529 spike 48 . Indeed, structural analysis of the B.1.1.529 spike protein in complex with hACE2 reveals new interactions formed by mutated residues in the RBD 48, 49 .

These in vivo studies were performed as part of the SAVE/NIAID consortium and reflect a network that communicates weekly to expedite progress on SARS-CoV-2 variants. This format had several advantages: animal experiments were reproduced across laboratories providing confidence in results; several B.1.1.529 isolates were tested limiting the possibility of sequence adaptations in a strain from one laboratory that could skew results; several strains of mice and hamsters at different ages were tested allowing for a comprehensive dataset; and the groups used overlapping metrics to evaluate infection and disease in the different animal models.

We note several limitations to our study. First, our experiments reflect data from a consortium that did not use uniform study design and metrics, which created variability in outcomes; despite this, data from several groups indicate that B.1.1.529 is attenuated in rodent models. Second, although attenuation of B.1.1.529 in mice and hamsters correlates with preliminary data in humans, evaluation in nonhuman primates and unvaccinated, previously uninfected humans is needed for corroboration. Third, we used the prevailing B.1.1.529 isolate that lacks an R346K substitution. Approximately 10% of B.1.1.529 sequences in GISAID as of the writing of this paper have an R346K sequence, and this substitution or others in gene products apart from spike might affect virulence. Although one of the B.1.1.529 isolates we tested contains an additional A701V change in spike near the furin cleavage site, it was still attenuated in mice. Fourth, detailed pathological and immunological analyses were not performed for all of the animal species studied. It remains possible that B.1.1.529 is attenuated clinically (for example, weight loss) because of defects in promoting pathological host responses.

In summary, our collective studies rapidly and reproducibly demonstrated attenuated infection in several strains of mice and hamsters. Experiments are ongoing to determine the basis for attenuation in mice and hamsters and to determine how this relates to B.1.1.529 infection in humans.

Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at https://doi.org/10.1038/s41586-022-04441-6.

Vero-TMPRSS2 (refs. 35, 50, 51 ) and Vero-hACE2-TMPRSS2 (ref. 52 ) cells were cultured at 37 °C in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 10 mM HEPES pH 7.3 and 100 U ml −1 penicillin-streptomycin. Vero-TMPRSS2 cells were supplemented with 5 µg ml −1 blasticidin or 1 mg ml −1 geneticin (depending on the cell line) and in some cultures with Plasmocin. Vero-hACE2-TMPRSS2 cells were supplemented with 10 µg ml −1 puromycin. All cells routinely tested negative for mycoplasma using a PCR-based assay.

The WA1/2020 recombinant strains with substitutions (D614G and/ or N501Y/D614G) were described previously 53 54 . All viruses were subjected to next-generation sequencing as described previously 55 to confirm the stability of substitutions and avoid introduction of adventitious alterations All virus experiments were performed in an approved biosafety level 3 facility.

Animal studies were carried out in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocols were approved by the Institutional Animal Care and Use Committee at the Washington University School of Medicine (assurance number A3381-01), University of Wisconsin, Madison (V006426), St Jude Children's Research Hospital (assurance number D16-00043), Emory University, University of Iowa (assurance number A3021-01), Icahn School of Medicine at Mount Sinai (PROTO202100007), BIOQUAL, Inc., and the Animal Experiment Committee of the Institute of Medical Science, the University of Tokyo (approval numbers PA19-72 and PA19-75). Virus inoculations were performed under anaesthesia that was induced and maintained with ketamine hydrochloride and xylazine, and all efforts were made to minimize animal suffering. In vivo studies were not blinded, and animals were randomly assigned to infection groups. No sample-size calculations were performed to power each study. Instead, sample sizes were determined based on previous in vivo virus challenge experiments.

Heterozygous K18-hACE2 C57BL/6J mice (strain 2B6.Cg-Tg (K18-ACE2)2Prlmn/J), 129 mice (strain 129S2/SvPasCrl or 129S1/SvImJ) and C57BL/6 (strain 000664) mice were obtained from The Jackson Laboratory and Charles River Laboratories. BALB/c mice were purchased from Japan SLC Inc. Animals were housed in groups and fed standard chow diets. Infection experiments were performed as follows. In a first set of experiments, 5-month-old female K18-hACE2 mice were inoculated intranasally with 10 3 , 10 4 or 10 5 FFU of SARS-CoV-2. In a second set of experiments, 129S1 male and female mice were used between 10 and 20 weeks of age. Mice were anaesthetized with isoflurane and inoculated intranasally with virus (50 µl, 10 6 PFU per mouse). In a third set of experiments, 6-week-old female BALB/c mice were inoculated intranasally with 10 5 PFU of hCoV-19/Japan/NC928-2N/2021 or hCoV-19/USA/MD-HP01542/2021. In a fourth set of experiments, retired breeder female C57BL/6 mice (10 to 14 months old) were anaesthetized with ketamine-xylazine and inoculated intranasally with SARS-CoV-2 in a total volume of 50 µl DMEM. Animal weight and health were monitored daily. In a fifth set of experiments, 6-8-week-old female 129S1 mice and 6-month-old female K18-hACE2 mice were inoculated intranasally under light ketamine-xylazine sedation with 10 4 PFU of hCoV-19/USA/NY-MSHSPSP-PV44476/2021 or hCoV-19/USA/ NY-MSHSPSP-PV44488/2021 in a total volume of 50 µl.

Male 5-6-week-old Syrian golden hamsters were obtained from Charles River Laboratories, Envigo or Japan SLC Inc. The K18-hACE2 transgenic hamster line was developed with a piggyBac-mediated transgenic approach, in which the K18-hACE2 cassette from the pK18-hACE2 plasmid 14 was transferred into a piggyBac vector, pmhyGENIE-3 (ref. 56 ), for pronuclear injection. hACE2 transgenic hamsters will be described in detail elsewhere 39 . Female 12-month-old transgenic animals were used. Infection experiments were performed as follows. In a first set of experiments, animals were challenged intranasally with 10 3 PFU of WA1/2020 D614G or B.1.1.529 variant in 100 µl. In a second set of experiments, under isoflurane anaesthesia, wild-type Syrian hamsters were intranasally inoculated with 10 3 PFU of SARS-CoV-2 strains in 30 µl. Body weight was monitored daily. For virological and pathological examinations, four hamsters per group were euthanized at 3 and 6 dpi, and nasal turbinates and lungs were collected. The virus titres in the nasal turbinates and lungs were determined by plaque assays on Vero-TMPRSS2 cells. Human ACE2 transgenic hamsters were intranasally inoculated with 10 3 PFU of HP-095 D614G or B.1.1.529 (hCoV-19/ USA/WI-WSLH-221686/2021) in 50 µl. Body weight and survival were monitored daily, and nasal turbinates and lungs were collected at 3 and 5 dpi for virological analysis. In a third set of experiments, six-week-old male Syrian golden hamsters were randomized into groups of 4 to 6 and inoculated with SARS-CoV-2 via delivery of 100 µl of appropriately diluted virus in PBS equally split between both nostrils. Weight change and clinical observations were collected daily. In a fourth set of experiments, while under isoflurane anaesthesia, male 8-10-week-old hamsters were inoculated intranasally with 10 4 PFU of WA1/2020 or B.1.1.529 in 100 µl volume. Body weight and survival were monitored daily. Nasal washes were taken at 4 dpi for virological analysis.

Mouse studies. Tissues were weighed and homogenized with zirconia beads in a MagNA Lyser instrument (Roche Life Science) in 1,000 µl DMEM medium supplemented with 2% heat-inactivated FBS. Tissue homogenates were clarified by centrifugation at 10,000 r.p.m. for 5 min and stored at −80 °C. RNA was extracted using the MagMax mirVana Total RNA isolation kit (Thermo Fisher Scientific) on the Kingfisher Flex extraction robot (Thermo Fisher Scientific). Viral RNA (N gene) was reverse transcribed and amplified using the TaqMan RNA-to-CT 1-Step Kit (Thermo Fisher Scientific), and data were analysed and normalized as described previously 57 . Infectious virus titres were determined by plaque assay on Vero-hACE2-TMPRSS2 cells as previously published 24 . The viral titres in the nasal turbinates and lungs were determined by plaque assay on Vero-TMPRSS2 cells as previously published 51 . At the indicated day post infection, mice were euthanized with isoflurane overdose and one lobe of lung tissue was collected in an Omni Bead ruptor tube filled with Tri Reagent (Zymo, number R2050-1-200). Tissue was homogenized using an Omni Bead Ruptor 24 (5.15 ms, 15 s), and then centrifuged to remove debris. RNA was extracted using a Direct-zol RNA MiniPrep Kit (Zymo, number R2051), and then converted to cDNA using a High-capacity Reverse Transcriptase cDNA Kit (Thermo, number 4368813). SARS-CoV-2 RNA-dependent RNA polymerase and subgenomic RNA were measured as described previously 29, 58 .

How bad is Omicron? What scientists know so far

Covid-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear

But mouse, you are not alone: on some severe acute respiratory syndrome coronavirus 2 variants infecting mice

Evidence for a mouse origin of the SARS-CoV-2 Omicron variant

Animal models for COVID-19

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells

Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms

SARS-CoV-2 serologic assays in control and unknown populations demonstrate the necessity of virus neutralization testing

Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS

Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus

Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2

SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function

A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies

Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment

The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice

A mouse model of SARS-CoV-2 infection and pathogenesis

SARS-CoV-2 causes lung infection without severe disease in human ACE2 knock-in mice

The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera

Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy

In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains

Intranasal immunization with a vaccinia virus vaccine vector expressing pre-fusion stabilized SARS-CoV-2 spike fully protected mice against lethal challenge with the heavily mutated mouse-adapted SARS2-N501Y MA30 strain of SARS-CoV-2

A mouse-adapted SARS-CoV-2 induces acute lung injury and mortality in standard laboratory mice

A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures

Eicosanoid signaling as a therapeutic target in middle-aged mice with severe COVID-19

CCR2 signaling restricts SARS-CoV-2 infection

Mouse-adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

Pathogenesis and transmission of SARS-CoV-2 in golden hamsters

Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development

Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains

Characterization of a new SARS-CoV-2 variant that emerged in Brazil

Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection

Radiological Society of North America expert consensus statement on reporting chest CT findings related to COVID-19. Endorsed by the Society of Thoracic Radiology, the American College of Radiology, and RSNA -Secondary Publication

Broad host range of SARS-CoV-2 predicted by comparative and structural analysis of ACE2 in vertebrates

Protection of human ACE2 transgenic Syrian hamsters from SARS CoV-2 variants by human polyclonal IgG from hyper-immunized transchromosomic bovines

for Childhood Infections and Vaccines of Children's Healthcare of Atlanta

11 Department of Animal Dairy, and Veterinary Sciences, College of Agriculture and Applied Sciences

One-Health Consortium and One-Health Genomic Laboratory

17 Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai

22 The Tisch Cancer Institute, Icahn School of Medicine at Mount

Epidemiological characterisation of the first 785 SARS-CoV-2 Omicron variant cases in Denmark

How bad is Omicron? Some clues are emerging

SARS-CoV-2 Omicron variant replication in human respiratory tract ex vivo

The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters

Isolation of SARS-CoV-2 B.1.1.28.2 (P2) variant and pathogenicity comparison with D614G variant in hamster model

Enhanced fitness of SARS-CoV-2 variant of concern Alpha but not Beta

SARS-CoV-2 infection and transmission in the North American deer mouse

COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice

SARS-CoV-2 Omicron variant: ACE2 binding, cryo-EM structure of spike protein-ACE2 complex and antibody evasion

Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement

TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes

Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

Spike mutation D614G alters SARS-CoV-2 fitness

Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung

mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates

Generation of transgenic pigs by cytoplasmic injection of piggyBac transposase-based pmGENIE-3 plasmids

Growth, detection, quantification, and inactivation of SARS-CoV-2

CCR2 signaling restricts SARS-CoV-2 infection

Sterilizing immunity against SARS-CoV-2 infection in mice by a single-shot and lipid amphiphile imidazoquinoline TLR7/8 agonist-adjuvanted recombinant spike protein vaccine

Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an outbreak of pneumonia

SARS-CoV-2 interference of influenza virus replication in Syrian hamsters

CT imaging features of 2019 novel coronavirus (2019-nCoV)

The subgenomic SARS-CoV-2 RNA levels were quantified in nasal turbinates and lungs by quantitative PCR with reverse transcription as previously published 29, 55 . Infectious virus titres in nasal turbinates and lungs were determined by plaque assay on Vero-TMPRSS2 cells as described previously 59 .Hamster studies. Lungs were collected 4 dpi and homogenized in 1.0 ml of DMEM, clarified by centrifugation (1,000 g for 5 min) and stored at −80 °C. Nasal washes were clarified by centrifugation (2,000 g for 10 min) and the supernatant was stored at −80 °C. To quantify viral load in lung tissue homogenates and nasal washes, RNA was extracted from 100 µl samples using E.Z.N.A. Total RNA Kit I (Omega) and eluted with 50 µl of water. Four microlitres of RNA was used for real-time quantitative PCR with reverse transcription to detect and quantify the N gene of SARS-CoV-2 using TaqMan RNA-to-CT 1-Step Kit (Thermo Fisher Scientific) as described previously 60 . The virus titres in the nasal turbinates and lungs were determined by plaque assay on Vero E6 cells expressing human TMRPSS2 as previously published 61 . RNA was extracted from clarified nasal washes using the Qiagen RNeasy extraction kit (Qiagen) following the manufacturer's instructions. Samples were purified on the included columns and eluted in 50 µl of nuclease-free water. PCR was conducted using 4× TaqMan Fast Virus Master Mix (Thermo Fisher) and an N-gene primer/probe set.

Vero-TMPRSS2 or Vero-TMPRSS2-hACE2 cells were seeded at a density of 1 × 10 5 cells per well in 24-well tissue culture plates. The following day, medium was removed and replaced with 200 µl of material to be titrated diluted serially in DMEM supplemented with 2% FBS. One hour later, 1 ml of methylcellulose overlay was added. Plates were incubated for 72 h, and then fixed with 4% paraformaldehyde (final concentration) in PBS for 20 min. Plates were stained with 0.05% (w/v) crystal violet in 20% methanol and washed twice with distilled, deionized water.

Superior and middle lobes of the lungs from K18-hACE2 mice (mock-infected or 3 dpi) were collected, homogenized and then stored at −80 °C. After thawing, lung homogenates were centrifuged at 10,000g for 5 min at 4 °C. Samples were inactivated with ultraviolent light in a clear, U-bottom 96-well plate (Falcon). A mouse 26-plex, bead-based Luminex assay (catalogue number EPXR260-26088-901) was used to profile cytokine and chemokine levels in clarified lung supernatants. The assay was performed according to the manufacturer's instructions, and all incubation steps occurred on an orbital shaker set at 300 r.p.m. Briefly, 50 µl of clarified lung homogenate supernatant was combined with beads in a lidded, black 96-well plate supplied as part of the kit and incubated for 30 min at room temperature, and then overnight at 4 °C. The next day, the plate was allowed to equilibrate to room temperature for 30 min, washed 3 times with 150 µl per well of 1× wash buffer diluted, and then 25 µl per well of 1× detection antibody mixture was added for 30 min at room temperature. The plate was washed 3 times, and then 50 µl per well of 1× Streptavidin-PE solution was added for 30 min at room temperature. After washing 3 times, 120 µl per well of reading buffer was added, and the plate was incubated for 5 min at room temperature. Data were acquired on a Luminex 100/200 analyser (Millipore) with xPONENT software (version 4.3) and analysed using GraphPad Prism (version 8.0) and R (version 4.0.5).

Hamsters were inoculated intranasally with 10 3 PFU (in 30 µl) of B.1.1.529 (strain NC928), B.1.617.2 (UW-5250) or PBS. Lungs of the infected animals were imaged by using an in vivo micro-CT scanner (CosmoScan FX; Rigaku Corporation). Under ketamine-xylazine anaesthesia, the animals were placed in the image chamber and scanned for 2 min at 90 kV, 88 µA, field of view 45 mm and pixel size 90.0 µm. After scanning, the lung images were reconstructed by using the CosmoScan Database software of themicro-CT (Rigaku Corporation) and analysed by using the manufacturer-supplied software. A CT severity score, adapted from a human scoring system, was used to grade the severity of the lung abnormalities 62 . Each lung lobe was analysed for degree of involvement and scored from 0 to 4 depending on the severity: 0 (none, 0%), 1 (minimal, 1%-25%), 2 (mild, 26%-50%), 3 (moderate, 51%-75%) or 4 (severe, 76%-100%). Scores for the five lung lobes were summed to obtain a total severity score of 0-20, reflecting the severity of abnormalities across the three infected groups. Images were anonymized and randomized; the scorer was blinded to the group allocation.

Excised animal tissues were fixed in 4% paraformaldehyde in PBS, and processed for paraffin embedding. The paraffin blocks were cut into 3-µm-thick sections and mounted on silane-coated glass slides. Sections were processed for in situ hybridization using an RNA scope 2.5 HD Red Detection kit (Advanced Cell Diagnostics) with an antisense probe targeting the nucleocapsid gene of SARS-CoV-2 (Advanced Cell Diagnostics). Lung tissue sections were scored for pathology on the basis of the percentage of alveolar inflammation in a given area of a pulmonary section collected from each animal in each group using the following scoring system: 0, no pathological change; 1, affected area (≤10%); 2, affected area (<50%, >10%); 3, affected area (≥50%); an additional point was added when pulmonary edema and/or alveolar haemorrhage was observed.

All reagents described in this paper are available through material transfer agreements.

The number of independent experiments and technical replicates used are indicated in the relevant figure legends. Statistical analysis included unpaired t-tests, Mann-Whitney tests and ANOVA with multiple correction post tests.

Further information on research design is available in the Nature Research Reporting Summary linked to this paper.

All data supporting the findings of this study are available in the paper. There are no restrictions in obtaining access to primary data. Source data are provided with this paper.

No code was used in the course of the data acquisition or analysis. 

The online version contains supplementary material available at https://doi.org/10.1038/s41586-022-04441-6. Correspondence and requests for materials should be addressed to Adrianus C. M. Boon, Michael S. Diamond or Yoshihiro Kawaoka. Peer review information Nature thanks Emmie de Wit and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Reprints and permissions information is available at http://www.nature.com/reprints.